Explore

Trendline Trendline
Johnson Johnson Exceeds Q1 2026 Expectations, Raises Revenue Outlook Amid Strategic Growth

Johnson Johnson Exceeds Q1 2026 Expectations, Raises Revenue Outlook Amid Strategic Growth

Johnson Johnson Exceeds Q1 2026 Expectations, Raises Revenue Outlook Amid Strategic Growth
Trendline Trendline
Johnson Johnson Sets Ambitious $100 Billion Revenue Target for 2026

Johnson Johnson Sets Ambitious $100 Billion Revenue Target for 2026

Johnson Johnson Sets Ambitious $100 Billion Revenue Target for 2026
Trendline Trendline
Johnson Johnson Aims for $100 Billion Revenue in 2026 Following Strong Q1 Performance

Johnson Johnson Aims for $100 Billion Revenue in 2026 Following Strong Q1 Performance

Johnson Johnson Aims for $100 Billion Revenue in 2026 Following Strong Q1 Performance
Trendline Trendline
Johnson Johnson Increases Quarterly Dividend by 3.1%, Marking 64th Consecutive Year of Growth

Johnson Johnson Increases Quarterly Dividend by 3.1%, Marking 64th Consecutive Year of Growth

Johnson Johnson Increases Quarterly Dividend by 3.1%, Marking 64th Consecutive Year of Growth
Reuters Reuters
J&J's first-quarter profit beats estimates even as Stelara sales disappoint

J&J's first-quarter profit beats estimates even as Stelara sales disappoint

By Michael Erman April 14 (Reuters) - Johnson & Johnson reported first-quarter earnings that beat Wall Street expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its
Trendline Trendline
Johnson Johnson Reports Strong Q1 2026 Results and Raises Annual Outlook

Johnson Johnson Reports Strong Q1 2026 Results and Raises Annual Outlook

Johnson Johnson Reports Strong Q1 2026 Results and Raises Annual Outlook
Trendline Trendline
Johnson Johnson Reports Strong Q1 2026 Results, Raises Annual Outlook

Johnson Johnson Reports Strong Q1 2026 Results, Raises Annual Outlook

Johnson Johnson Reports Strong Q1 2026 Results, Raises Annual Outlook
Trendline Trendline
Johnson Johnson's Strategic Transformation in 2026

Johnson Johnson's Strategic Transformation in 2026

Johnson Johnson's Strategic Transformation in 2026
Trendline Trendline
Johnson Johnson Increases Quarterly Dividend for 64th Consecutive Year

Johnson Johnson Increases Quarterly Dividend for 64th Consecutive Year

Johnson Johnson Increases Quarterly Dividend for 64th Consecutive Year
Trendline Trendline
Revolution Medicines Reports Positive Phase 3 Results for Pancreatic Cancer Treatment, Boosting Market Value

Revolution Medicines Reports Positive Phase 3 Results for Pancreatic Cancer Treatment, Boosting Market Value

Revolution Medicines Reports Positive Phase 3 Results for Pancreatic Cancer Treatment, Boosting Market Value
Trendline Trendline
Viatris Announces Upcoming First Quarter 2026 Financial Results Release

Viatris Announces Upcoming First Quarter 2026 Financial Results Release

Viatris Announces Upcoming First Quarter 2026 Financial Results Release
Trendline Trendline
Biotech Companies Alamar, Hemab, Kailera, and Seaport Advance IPO Plans on Nasdaq

Biotech Companies Alamar, Hemab, Kailera, and Seaport Advance IPO Plans on Nasdaq

Biotech Companies Alamar, Hemab, Kailera, and Seaport Advance IPO Plans on Nasdaq